Skip to content
zameds

Phenylpropanolamine (Equi-sinus, Equi-decon)

Phenylpropanolamine

Mothopo pharma chem

Registration

Applicant
Mothopo pharma chem
Registrations
2

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Equi-sinus drops

EACH 0,50 ml DROPS CONTAINS: PHENYLPROPANOLAMINE HYDROCHLORIDE 25,0 mg

Drops35036935/16.1/0369RegisteredNot determinedNone
Equi-decon oral drops

EACH 0,5 ml SOLUTION CONTAINS PHENYLPROPANOLAMINE HYDROCHLORIDE 25,0 mg

Oral drops35037835/16.1/0378RegisteredNot determinedNone

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

  • S6: Phenylpropanolamine

    • except products registered in terms of the Act, not intended for export and oral preparations and mixtures where the recommended daily dose for adults does not exceed 100 milligrams and for children 6 to 12 years does not exceed 50 milligrams, when in combination with another pharmacologically active substance and intended for the symptomatic relief of nasal and sinus congestion, subject to a maximum pack size of 300 milligrams for adults and 150 milligrams for children, limited to one pack per customer. (S2)

    Consolidated Schedules 06 July 2026, lines 10387 to 10394

  • S2: Phenylpropanolamine

    • contained in products registered in terms of the Act, and not intended for export, unless listed separately in the Schedules,
    • oral preparations and mixtures where the recommended daily dose for adults does not exceed 100 milligrams and for children 6 to 12 years does not exceed 50 milligrams, when in combination with another pharmacologically active substance and intended for the symptomatic relief of nasal and sinus congestion, subject to a maximum pack size of 300 milligrams for adults and 150 milligrams for children, limited to one pack per customer. (S6)

    Consolidated Schedules 06 July 2026, lines 2516 to 2523

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

C9H13NO151.21 g/mol

(1R,2S)-2-Amino-1-phenylpropan-1-ol

Drag to rotate. Structure from PubChem CID 10297.

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Background

Loading...
Loading Wikipedia summary

Research articles

Loading...
Loading PubMed articles